Eguchi K, Shimizu E, Shinkai T, Tominaga K, Saijo N, Shimabukuro Z, Shibuya M, Niitani H
Gan No Rinsho. 1984 Feb;30(2):115-21.
Randomized trials were sequentially performed in SCLC patients using a two-drug combination (ACNU . VCR, ADM . VCR) and a three-drug combination (ACNU . CPA . VCR, ACNU . ADM . VCR). The response rate for the two-drug regimen was 36.4% (8/22 cases) and that for the three-drug combination was 60.0% (15/25 cases). The median survival time of the two groups was 7 and 9 months, respectively. The group with PS. 0-1 showed a better prognosis than that with PS. 2-3 (p = 0.03). No fatal side effects were experienced in this protocol. These data suggest that the three-drug combination (ACNU . VCR . CPA) represents an active regimen for SCLC.
在小细胞肺癌患者中依次进行了随机试验，采用两药联合方案（嘧啶亚硝脲.长春新碱、阿霉素.长春新碱）和三药联合方案（嘧啶亚硝脲.环磷酰胺.长春新碱、嘧啶亚硝脲.阿霉素.长春新碱）。两药方案的缓解率为36.4%（22例中的8例），三药联合方案的缓解率为60.0%（25例中的15例）。两组的中位生存时间分别为7个月和9个月。PS评分为0 - 1的组比PS评分为2 - 3的组预后更好（p = 0.03）。该方案未出现致命的副作用。这些数据表明，三药联合方案（嘧啶亚硝脲.长春新碱.环磷酰胺）是小细胞肺癌的一种有效治疗方案。
